Application of genomic and proteomic technologies to early detection of cancer

Archives of Iranian Medicine

Volumn 11, Issue 4, 2008, Pages 427-434

  Ardekani, Ali M ^a   Akhondi, Mohammad Mehdi ^a   Sadeghi, Mohammad Reza ^a  

^a AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

Cancer; Early detection; Genomics; Proteomics; SELDI TOF

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; IMATINIB; LYSOPHOSPHATIDIC ACID; PROGESTERONE RECEPTOR; PROTEIN P21; PROTEIN P53; PROTEOME; RNA; TAMOXIFEN; TRANSCRIPTOME; TRASTUZUMAB;

BIOINFORMATICS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING; CANCER SURVIVAL; CELL ISOLATION; CELL POPULATION; CHRONIC MYELOID LEUKEMIA; COMPARATIVE GENOMIC HYBRIDIZATION; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ENDOMETRIUM CARCINOMA; EXPRESSED SEQUENCE TAG; FALSE POSITIVE RESULT; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENOMICS; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LASER CAPTURE MICRODISSECTION; LUNG NON SMALL CELL CANCER; MAMMOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROARRAY ANALYSIS; OVARIECTOMY; OVARY CANCER; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; RNA TRANSLATION; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TRANSVAGINAL ECHOGRAPHY; TWO DIMENSIONAL GEL ELECTROPHORESIS; UTERINE CERVIX CANCER; WART VIRUS; WESTERN BLOTTING;

EARLY DETECTION OF CANCER; GENOMICS; HUMANS; PROTEOMICS;

EID: 48449084487     PISSN: 10292977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science. 2001; 291: 1304-1351.
2. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001; 409: 860-921.
3. Michener CM, Ardekani AM, Petricoin EF 3rd, Liotta LA, Kohn EC. Genomics and Proteomics: Application of vovel technology to early detection and prevention of cancer. Cancer Detect Prev. 2002; 26: 249-255.
4. Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, et al. Laser capture microdissection. Science. 1996; 274: 998-1001.
5. Bonner RF, Emmert-Buck MR, Cole K, Pohida T, Chuaqui RF, Goldstein S, et al. Laser capture microdissection: molecular analysis of tissue. Science. 1997; 278: 1481-1483.
6. Jares P, Campo E. Genomic platforms for cancer research: potential diagnostic and prognostic applications in clinical oncology. Clin Transl Oncol. 2006; 8: 161-172.
7. Chung CH, Levy S, Chaurand P, Carbone DP. Genomics and proteomics: emerging technologies in clinical cancer research. Crit Rev Oncol Hematol. 2007; 61: 1-25.
8. Petricoin EF 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst. 2002; 94: 1576-1578.
9. Mittal V, Nolan DJ. Genomics and proteomics approaches in understanding tumor angiogenesis. Expert Rev Mol Diagn. 2007; 7: 133-147.
10. Ries LAG, Miller BA, Hankey BF, Kosary CL, Harris A, Edwards BK. SEER Cancer Statistics Review 1973-1991. Bethesda, MD: National Cancer Institute. 1994; 136-144.
11. Hatch KD, Schneider A, Abdel-Nour MW. An evaluation of human papillomavirus testing for intermediate- and high-risk types as triage before colposcopy. Am J Obstet Gynecol. 1995; 172: 1150-1155.
12. Bernard HU, Chan SY, Manos MM, Ong CK, Villa LL, Delius H, et al. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis. 1994; 170: 1077-1085.
13. Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA. 1991; 265: 472-477.
14. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER-2 antibody (Herceptin) enhances the anti-tumor activity of paclitaxel and doxorubicin against HER-2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998; 58: 2825-2831.
15. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER-2/neu monoclonal antibody plus cisplatin in patients with HER-2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998; 16: 2659-2671.
16. Harkin DP. Genomics and the impact of new technologies on the management of colorectal cancer. Cancer. 2006; 11: 988-991.
17. Franzen B, Hirano T, Okuzawa K, Uryu K, Alaiya AA, Linder S, et al. Sample preparation of human tumors prior to two-dimensional electrophoresis of proteins. Electrophoresis. 1995; 16: 1087-1089.
18. Zvibel I, Brill S, Papa M, Halpern Z. Hepatocyte-derived soluble factors regulate proliferation and autocrine growth factor expression in colon cancer cell lines of varying liver-colonizing capability. Tumour Biol. 2000; 21: 187-196.
19. Bemis LT, Schedin P. Reproductive state of rat mammary gland stroma modulates human breast cancer cell migration and invasion. Cancer Res. 2000; 60: 3414-3418.
20. Chung LW. Fibroblasts are critical determinants in prostatic cancer growth and dissemination. Cancer Metastasis Rev. 1991; 10: 263-274.
21. Berger SJ, DeVries GW, Carter JG, Schulz DW, Passonneau PN, Lowry OH, et al. The distribution of the components of the cyclic GMP cycle in retina. J Biol Chem. 1980; 255: 3128-3133.
22. Radford DM, Fair K, Thompson AM, Ritter JH, Holt M, Steinbrueck T, et al. Allelic loss on a chromosome 17 in ductal carcinoma in situ of the breast. Cancer Res. 1993; 53: 2947-2949.
23. Liotta LA, Kohn EC. The microenvironment of the tumor-host interface. Nature. 2001; 411: 375-379.
24. Fend F, Emmert-Buck MR, Chuaqui R, Cole K, Lee J, Liotta LA, et al. Immuno-LCM: laser capture microdissection of immunostained frozen sections for mRNA analysis. Am J Pathol. 1999; 154: 61-66.
25. Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics. 2002; 2: 76-84.
26. Ornstein DK, Gillespie JW, Paweletz CP, Duray PH, Herring J, Vocke CD, et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis. 2000; 21: 2235-2242.
27. Bielas JH, Venkatesan RN, Loeb LA. LOH-proficient embryonic stem cells: a model of cancer progenitor cells? Trends Genet. 2007; 23: 154-157.
28. Sobol H, Benziane A, Kerangueven F, Yin L, Noguchi T, Pauly S, et al. Genome-wide search for loss of heterozygosity in Burkitt lymphoma cell lines. Genes Chromosomes Cancer. 2002; 33: 217-224.
29. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999; 21: 99-102.
30. Choi YW, Bae SM, Kim YW, Lee HN, Park TC, RO DY, et al. Gene expression profiles in squamous cell cervical carcinoma using array-based comparative genomic hybridization analysis. Int J Gynecol Cancer. 2007; 17: 687-696.
31. Kloth JN, Oosting J, van Wezel T, Szuhai K, Knijnenburg J, Gorter A, et al. Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer. BMC Genomics. 2007; 8: 53-62.
32. Wadlow R, Ramaswamy S. DNA microarrays in clinical cancer research. Curr Mol Med. 2005; 5: 111-120.
33. Fodor SP, Rava RP, Huang XC, Pease AC, Holmes CP, Adams CL. Multiplexed biochemical assays with biological chips. Nature. 1993; 364: 555-556.
34. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet. 1996; 14: 457-460.
35. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, et al. Gene expression profiles in normal and cancer cells. Science. 1997; 276: 1268-1272.
36. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science. 1995; 270: 484-487.
37. MacBeath G, Schreiber SL. Printing proteins as microarrays for high-throughput function determination. Science. 2000; 289: 1760-1763.
38. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707-712.
39. Bur ME, Perlman C, Edelmann L, Fey E, Rose PG. p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol. 1992; 98: 81-87.
40. Hale RJ, Buckley CH, Gullick WJ, Fox H, Williams J, Wilcox FL. Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. J Clin Pathol. 1993; 46: 149-153.
41. Kwiatkowski DJ, Harpole DH Jr, Godleski J, Herndon JE 2nd, Shieh DB, Richards W, et al. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol. 1998; 16: 2468-2477.
42. Chung YL, Sheu ML, Yang SC, Lin CH, Yen SH. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer. 2002; 97: 306-312.
43. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989; 320: 479-484.
44. Lueking A, Horn M, Eickhoff H, Büssow K, Lehrach H, Walter G. Protein microarrays for gene expression and antibody screening. Anal Biochem. 1999; 270: 103-111.
45. Vasiliskov AV, Timofeev EN, Surzhikov SA, Drobyshev AL, Shick VV, Mirzabekov AD. Fabrication of microarray of gel-immobilized compounds on a chip by copolymerization. Biotechniques. 1999; 27: 592-606.
46. Emmert-Buck MR, Strausberg RL, Krizman DB, Bonaldo MF, Bonner RF, Bostwick DG, et al. Molecular profiling of clinical tissues specimens: feasibility and applications. J Mol Diagn. 2000; 2: 60-66.
47. Paweletz CP, Ornstein DK, Roth MJ, Bichsel VE, Gillespie JW, Calvert VS, et al. Loss of annexin-1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res. 2000; 60: 6293-6297.
48. Leak LV, Petricoin EF 3rd, Jones M, Paweletz CP, Ardekani AM, Fusaro VA, et al. Proteomic technologies to study diseases of the lymphatic vascular system. Ann N Y Acad Sci. 2002; 979: 211-234.
49. Ardekani AM, Petricoin EF, Joe Hacket. Molecular diagnostics: FDA Perspective. Expert Rev Mol Diag. 2003; 3: 129-140.
50. Petricoin EF, Rajapaske V, Herman EH, Arekani AM, Ross S, Johann D, et al. Toxicoproteomics: serum proteomic pattern diagnostics for early detection of drug induced cardiac toxicities and cardioprotection. Toxicol Pathol. 2004; 32: 122-130.
51. Michener CM, Ardekani AM, Petricoin EF, Liotta LA, Kohn EC. Genomics and proteomics: application of novel technology to early detection and prevention of cancer. Cancer Detect Prev. 2002; 26: 249-255.
52. Petricoin EF 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, et al. Serum proteomic patterns for the detection of prostate cancer. J Natl Cancer Inst. 2002; 94: 1576-1578.
53. DePriest PD, Gallion HH, Pavlik EJ, Kryscio RJ, van Nagell Jr JR. Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol. 1997; 65: 408-414.
54. van Nagell JR Jr, DePriest PD, Reedy MB, Gallion HH, Ueland FR, Pavlik EJ, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol. 2000; 77: 350-356.
55. Ardekani AM, Liotta LA, Petricoin EF. Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev Mol Diagn. 2002; 2: 312-320.
56. van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, et al. OVX1, Macrophage-colony stimulating factor, and CA125 II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer. 2001; 92: 2837-2844.
57. Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 1998; 280: 719-723.
58. Liotta LA, Petricoin EF 3rd, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, et al. General keynote: proteomic patterns in sera serve as biomarkers of ovarian cancer. Gynecol Oncol. 2003; 88: 25-42.